Insights Into Cannabis and Cannabinoids: Chemical Properties, Legal Perspectives, and Therapeutic Applications.
| Journal | Chemistry & biodiversity |
| Study Type | Randomized Trial |
| Population | Human participants |
This comprehensive review synthesizes evidence across cannabis medicine’s core domains—phytochemistry, pharmacology, clinical applications, and regulatory frameworks. For clinicians entering cannabis medicine, it provides a structured foundation for understanding the complexity of whole-plant therapeutics beyond isolated cannabinoids.
This systematic review examines over 500 identified cannabis compounds including cannabinoids, terpenes, flavonoids, and alkaloids across therapeutic domains of chronic pain, epilepsy, oncology, psychiatry, and inflammation. The authors integrate historical use patterns, phytochemical analysis, clinical trial data, and regulatory perspectives to map current evidence. Notable limitations include acknowledgment of dosing uncertainties, long-term safety gaps, and standardization challenges that persist across cannabis medicine. The review emphasizes evidence gaps requiring randomized controlled trials for evidence-based practice advancement.
“This review accurately captures both the therapeutic promise and clinical challenges I encounter daily—we have compelling mechanistic rationale and patient outcomes, yet dosing remains more art than science. The emphasis on standardization and rigorous trial design reflects the field’s maturation toward evidence-based practice.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What cannabis compounds and medical conditions does this review cover?
The review examines more than 500 identified cannabis compounds, including cannabinoids, terpenes, flavonoids and alkaloids. It looks at them across five therapeutic domains: chronic pain, epilepsy, oncology, psychiatry and inflammation. It was published in the journal Chemistry & Biodiversity.
Does this review address legal and regulatory aspects of cannabis?
Yes. The authors integrate regulatory perspectives together with historical use patterns, phytochemical analysis and clinical trial data. Combining these different kinds of information is how the review sets out to map the current evidence across cannabis medicine.
What gaps or limitations in cannabis medicine does the review identify?
The review acknowledges dosing uncertainties, long-term safety gaps and standardization challenges that persist across cannabis medicine. It emphasizes that these evidence gaps require randomized controlled trials for evidence-based practice to advance.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
